School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, Australia.
Department of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo, Brazil.
Cancer Treat Rev. 2022 Nov;110:102439. doi: 10.1016/j.ctrv.2022.102439. Epub 2022 Jul 26.
Clinically, HPV-positive oropharyngeal cancers (OPCs) have been shown to have a distinct prognosis, compared to HPV-negative tumours, particularly in survival rates and responses to treatment. These patients have better survival chances and improved prognosis, indicating that a more exhaustive knowledge of these distinctions would aid in the discovery of clinical approaches for both HPV-positive and negative tumours. Furthermore, there is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular, and clinical distinct form as compared to non-HPV related ones therefore, the treatment of these specific subtype of oropharyngeal cancers should adopt a distinct clinical treatment pipeline. Our review will examine the current approaches for the diagnosis and treatment of OPC and discuss the relevance of de-escalation clinical trials in progress.
临床上，与 HPV 阴性肿瘤相比，HPV 阳性口咽癌（OPC）具有明显不同的预后，尤其是在生存率和治疗反应方面。这些患者的生存机会更好，预后改善，这表明更深入地了解这些差异将有助于发现 HPV 阳性和阴性肿瘤的临床治疗方法。此外，越来越多的证据表明，与 HPV 相关的口咽癌与非 HPV 相关的口咽癌在流行病学、分子和临床方面存在明显的不同，因此，这些特定亚型的口咽癌的治疗应该采用不同的临床治疗方案。我们的综述将检查 OPC 的当前诊断和治疗方法，并讨论正在进行的降阶临床试验的相关性。
